Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (Nasdaq: ALKS) is a global biopharmaceutical company focused on neuroscience, and its news flow reflects both commercial execution and clinical development in this area. Company announcements emphasize proprietary products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, alongside a growing pipeline targeting neurological disorders such as narcolepsy and idiopathic hypersomnia.
Recent news has highlighted alixorexton, Alkermes investigational oral, selective orexin 2 receptor agonist. The company has reported positive phase 2 data from the Vibrance-1 study in narcolepsy type 1 and the Vibrance-2 study in narcolepsy type 2, and has announced that alixorexton is being evaluated in the Vibrance-3 study in idiopathic hypersomnia. In a separate update, Alkermes disclosed that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to alixorexton for narcolepsy type 1, based on phase 1 and phase 2 data.
Investors following ALKS news will also see regular earnings releases, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, and provides updates to its financial expectations. These releases describe trends in proprietary product sales, including VIVITROL, ARISTADA and LYBALVI, and manufacturing and royalty revenues related to VUMERITY and certain long-acting antipsychotic products.
Another key theme in Alkermes news is corporate transactions and financing. The company has announced a transaction agreement, and later an amendment, to acquire Avadel Pharmaceuticals plc, adding LUMRYZ, an FDA-approved once-at-bedtime oxybate for narcolepsy, to its commercial portfolio if the transaction is completed. Related filings describe an amended and restated bridge term loan credit agreement designed to support financing of the proposed acquisition.
Visitors to the ALKS news page can expect updates on clinical trial milestones, regulatory designations, quarterly financial performance, investor conference participation and material corporate agreements. This mix of scientific, financial and strategic information provides context for understanding Alkermes evolving position in neuroscience and sleep medicine.
Alkermes plc (Nasdaq: ALKS) reported second-quarter 2022 revenues of $276.2 million, down from $303.7 million year-over-year. Proprietary product net sales increased to $190.8 million, driven by VIVITROL and ARISTADA. However, GAAP loss per share was $0.18, compared to a gain of $0.01 in the prior year. The company raised its full-year revenue expectations to $1,050 - $1,120 million, largely due to the successful launch of LYBALVI. Operating expenses rose to $310.7 million, reflecting increased investments.
Alkermes plc (Nasdaq: ALKS) will host a conference call on July 27, 2022 at 8:00 a.m. ET to discuss its second quarter financial results and provide updates on company progress. Interested parties can access the webcast via Alkermes' website, with a replay available two hours post-event. Alkermes focuses on developing medicines in neuroscience and oncology, with a portfolio addressing conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder.
Alkermes plc (Nasdaq: ALKS) reported the results of its 2022 Annual General Meeting held on July 7, 2022. All four nominees for the Board of Directors were re-elected with over 97% of shareholder votes. Additionally, the advisory vote on executive officer compensation passed with over 86% approval. Lead Independent Director Nancy J. Wysenski emphasized the strong support for the Board's refreshment efforts, highlighting the company's focus on strategic priorities and operational execution aimed at driving growth and shareholder value. Full vote results will be disclosed via SEC filing.
Sarissa Capital Management expresses concern over the influence of CEO Richard Pops on Alkermes' board. Despite Alkermes' revenues exceeding $1 billion, they report consistent net losses and a nearly 60% stock price drop over five years, underperforming the IBB by 130%. Sarissa supports newly appointed directors and plans to vote for their slate at the upcoming annual meeting. If a Sarissa representative is not appointed soon, they may pursue action under Irish law to replace certain board members to act in shareholders' best interests.
Alkermes plc (Nasdaq: ALKS) announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 2:40 p.m. PT (5:40 p.m. ET). The event will include a fireside chat with management, accessible via a live webcast on the company’s website and archived for 14 days. Alkermes, headquartered in Dublin, focuses on developing innovative medicines in neuroscience and oncology, with products for conditions like alcohol and opioid dependence, schizophrenia, and more.
Alkermes plc (Nasdaq: ALKS) is set to accept applications for its Alkermes Inspiration Grants program starting June 15, 2022. The program aims to distribute up to $500,000 in grants to nonprofit organizations focused on addressing the needs of individuals affected by addiction, serious mental illness, or cancer. This year's focus is on innovative programs targeting unmet needs, particularly in historically under-resourced communities. Eligible organizations can submit applications until July 15, 2022. More details are available on Alkermes' official website.
Alkermes plc (Nasdaq: ALKS) announced participation in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 2:30 p.m. ET. The event will be accessible via live webcast on Alkermes' website and archived for 14 days. Alkermes is a global biopharmaceutical firm focused on innovative treatments for conditions like alcohol and opioid dependence, schizophrenia, and bipolar I disorder. Headquartered in Dublin, Ireland, the company also has facilities in Massachusetts, Ohio, and Ireland.
Alkermes plc (Nasdaq: ALKS) is set to present positive data from the ARTISTRY-1 clinical trial, showcasing the anti-tumor activity of nemvaleukin as both a monotherapy and in combination with pembrolizumab (KEYTRUDA®). This phase 1/2 study revealed significant responses in difficult-to-treat tumors, including melanoma and renal cell carcinoma. The company will host an investor webcast on June 6, 2022, to discuss these findings further, emphasizing the potential for nemvaleukin in improving cancer therapy outcomes.
Sarissa Capital Management expresses serious concerns over the corporate governance of Alkermes (NASDAQ: ALKS), claiming the board is heavily influenced by CEO Richard Pops, who they allege has caused significant shareholder value destruction over 30 years. In a statement, Sarissa criticized the abrupt ending of discussions about director nominations and highlighted the board's neglect of shareholder interests. Despite Alkermes achieving over $1 billion in revenue from 2017-2021, the company consistently operated at a net loss while underperforming the IBB index by 130%.
Alkermes plc (Nasdaq: ALKS) announced the appointment of Nancy J. Wysenski as the new Lead Independent Director and the retirement of long-serving directors David W. Anstice AO and Wendy L. Dixon, Ph.D. The company also filed a preliminary proxy statement for its upcoming Annual General Meeting. Additionally, Christopher I. Wright, M.D., Ph.D., was appointed to the Board, bringing significant experience in neuroscience and drug development. These moves are part of Alkermes' ongoing commitment to corporate governance and board refreshment.